Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are allieviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.
Novel potent and selective Ca2+ release-activated Ca2+ (CRAC) channel inhibitors. Part 3: Synthesis and CRAC channel inhibitory activity of 4′-[(trifluoromethyl)pyrazol-1-yl]carboxanilides
From a series of 4 '-[(trifluoromethyl)pyrazol-1-yl]carboxanilides derived from 4-methyl-4 '-[3,5-bis(tri- fluoromethyl)-1H-pyrazol-1-yl]-1,2,3-thiadiazole-5-carboxanilide, one inhibited thapsigargin-induced Ca(2+) influx in Jurkat T cells (IC(50) = 77 nM) and exhibited high selectivity for the CRAC channel over the VOC channel (index: > 130). Another acted as an inhibitor for both T lymphocyte activation-induced diseases and ovalbumin-induced airway eosinophilia in rats (ED(50) = 1.3 mg/kg) p.o. (C) 2008 Elsevier Ltd. All rights reserved.
WO2006/74264
申请人:——
公开号:——
公开(公告)日:——
VEKEMANS, JOZEF A. J. M.;BOOGERS, JEROEN A. F.;BUCK, HENK M., J. ORG. CHEM., 56,(1991) N, C. 10-16
作者:VEKEMANS, JOZEF A. J. M.、BOOGERS, JEROEN A. F.、BUCK, HENK M.